Glenmark Launches Zita DM: A Triple-Drug Combination for Type 2 Diabetes for just Rs 14

▴ Glenmark
Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of the diabetes management landscape, it holds the potential to positively impact the lives of millions of individuals suffering from this chronic condition.

Glenmark Pharmaceuticals Limited, a leading global pharmaceutical company, has introduced a groundbreaking solution for managing type 2 diabetes in India. The newly launched Zita DM is the country's first triple-drug fixed-dose combination (FDC) that combines teneligliptin with dapagliflozin and metformin, addressing the challenges faced by diabetic patients.

India, with the second-largest diabetic population globally, has witnessed the launch of Zita DM to enhance glycemic control in individuals with type 2 diabetes. This FDC, available under the brand name Zita DM, combines the widely-used teneligliptin (20mg), dapagliflozin (10mg), and metformin SR (500mg/1000mg) in a fixed dose, requiring only once-daily consumption under a prescription.

Addressing Unmet Needs: Alok Malik, President & Business Head - India Formulations at Glenmark Pharma, highlighted the challenges faced by type 2 diabetic patients in India, including uncontrolled HbA1c levels and beta cell dysfunction affecting insulin secretion. Zita DM aims to fill this gap by offering a robust solution that not only improves glycemic control but also addresses co-morbidities such as weight gain.

Glenmark's Zita portfolio, catering to around 1.75 million type 2 diabetic patients annually in India, has been a foundation in diabetes management. With the addition of Zita DM, the comprehensive gliptin range promises to assist type 2 diabetic patients at every stage of their treatment journey.

Affordability and Accessibility: Priced at Rs. 14 per tablet, Zita DM is positioned as an affordable anti-diabetic drug. This pricing strategy is expected to lower the daily cost of therapy by 30%, making the medication more accessible to a broader population.

Market Impact and Growth: The oral anti-diabetic drugs market in India, as per IQVIA sales data for the period ending August 2023, is estimated at Rs. 12,522 crore, with an annual growth rate of 6.5%. Zita DM's entry is poised to make a significant impact on this market, offering an innovative and effective treatment option.

Glenmark's Legacy in Diabetes Care: Glenmark has a strong legacy in providing effective and affordable treatment options for patients with uncontrolled type 2 diabetes. The company has consistently introduced innovative drugs and combinations, including DPP4 inhibitors, SGLT-2 inhibitors, and various FDCs, contributing to the evolving landscape of diabetes care in India.

In conclusion, the launch of Zita DM marks a significant milestone in the management of type 2 diabetes in India. Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of the diabetes management landscape, it holds the potential to positively impact the lives of millions of individuals suffering from this chronic condition

Tags : #glenmark #zitadm #diabetes #diabetescare #diabtesmanagement #FDC #pharmaceutical #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Why are key populations on the blindspot in the global HIV response?July 20, 2024
Exploring the Link Between Tinnitus and Body Composition: What Recent Research RevealsJuly 20, 2024
Surge in Brain Infections in India During Monsoon: A Growing ConcernJuly 20, 2024
We have more infection-prevention options now but are they actual choices for the people?July 19, 2024
New humidity-driven membrane to remove carbon dioxide from the airJuly 19, 2024
Introducing the World's First Consent-Based Data-Sharing Framework Built on Open Standards: The Affinidi Iota Framework July 19, 2024
The Power of Green Spaces: Evidence That Parks May Delay Cognitive DeclineJuly 19, 2024
Strengthening Healthcare in India: The Push for Better Coverage with Ayushman BharatJuly 19, 2024
SARV Events & Celebrations Shines at "Edu-Bizz Leadership Summit & Awards 24July 18, 2024
UAE launches global initiative to build 10 hospitals to address critical healthcare gaps as part of Zayed Humanitarian Legacy InitiativeJuly 18, 2024
Geetanjali Homestate Expands Global Presence with the Launch of Geetanjali GlobalJuly 18, 2024
Changes projected in marine fish communities due to climate changeJuly 18, 2024
Understanding the Chandipura Virus Outbreak in Gujarat: A Critical OverviewJuly 18, 2024
Landmark Study Links Severe Endometriosis to Increased Risk of Ovarian CancerJuly 18, 2024
Equipping Healthcare Professionals for Global Opportunities: GIMS Partners with NSDCJuly 18, 2024
Hormone Modulating Therapy for Breast Cancer and Its Link to Lower Alzheimer’s RiskJuly 18, 2024
Multipl Secures $1.5 Million in Additional Funds, Led by Blume Ventures and MIXI Global Investments, JapanJuly 17, 2024
FedEx to empower youth with digital skilling programJuly 17, 2024
Putting people first means following Gandhi's TalismanJuly 17, 2024
American Oncology Institute (AOI) Launches #BreaktheHabit Campaign to Raise Awareness on Head & Neck cancerJuly 17, 2024